瘤基因和Polycomb组基因bmi-1通过ink4a位点调节细胞增殖和衰老
J J Jacobs1, K Kieboom, S Marino
1Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam.
Nature
|January 29, 1999
概括
bmi-1基因是Polycomb组蛋白质,它调节细胞循环的进展和衰老. 它的缺失导致缺陷,而其过度表达导致淋巴瘤和癌症,突出其在瘤抑制中的作用.
科学领域:
- 分子生物学分子生物学
- 发展生物学 发展生物学
- 癌症研究 癌症研究
背景情况:
- Bmi-1 是一个Polycomb组蛋白质,在发育过程中参与基因沉默.
- Bmi-1的失调与癌症和发育异常有关.
- 聚合组蛋白质保持稳定的基因抑制,这对发育至关重要.
研究的目的:
- 研究bmi-1在细胞周期控制和衰老中的作用.
- 为了确定Bmi-1.的体内目标.
- 为了阐明Polycomb组蛋白,细胞循环调节和衰老之间的联系.
主要方法:
- 对bmi-1-缺乏的小鼠胚胎纤维细胞和淋巴细胞的分析.
- 细胞循环进展和衰老标记物的评估.
- 对瘤抑制剂p16和p19Arf (编码为ink4a) 的基因表达分析.
- 评估bmi-1过度表达对纤维细胞永生和转变的影响.
主要成果:
- bmi-1 缺乏会影响细胞循环的进展,并诱导纤维细胞的过早衰老.
- bmi-1缺乏导致瘤抑制剂p16和p19Arf的表达增加.
- bmi-1过度表达促进纤维细胞不朽化和瘤转变.
- 移除ink4a可以挽救bmi-1-缺乏的小鼠中的淋巴状和神经缺陷.
结论:
- Bmi-1 作为转录抑制剂,将多组蛋白与细胞循环控制和衰老联系起来.
- Ink4a是一种关键的体内向基因,由Bmi-1调节.
- Bmi-1在预防过早衰老和维持正常发育方面发挥着重要作用.
相关概念视频
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


